Medicines Co. Aktie
Finanztrends
Deine Einschätzung
Was spricht für und gegen Medicines Co. in den nächsten Jahren?
Pro
?
L*********** I********** f** d** n******* J****
?
W******* i* V********
?
M************
Kontra
?
U****************
?
A****************
?
M****
Sag uns deine Meinung, um die 'Wisdom of the Crowds' zu nutzen
Rendite von Medicines Co. im Vergleich
| Wertpapier | Ver.(%) | 1W | 1M | 1J | YTD | 3J | 5J |
|---|---|---|---|---|---|---|---|
| Medicines Co. | - | - | - | - | - | - | - |
| Repligen Corp. | 0,12 % | 0,65 % | 3,04 % | 13,82 % | -12,28 % | -21,80 % | -39,08 % |
| Opko Health Inc. | -2,54 % | 15,69 % | -9,92 % | 5,89 % | 8,24 % | -27,55 % | -59,96 % |
| Guangzhou Baiyunshan Pharmaceutical Holdings Co. Ltd. | -0,58 % | 1,72 % | 11,32 % | -11,50 % | -9,69 % | -34,44 % | -19,55 % |
Kommentare
News
Amneal Pharmaceuticals Q2 Earnings Call Highlights
Key Points
- Interested in Amneal Pharmaceuticals, Inc.? Here are five stocks we like better.
- Amneal reported strong Q2 results, with revenue up 10% to $796 million, adjusted EBITDA up 12% to
Meet the Stock That's Obliterating Eli Lilly, Johnson & Johnson, and AbbVie Right Now
Shares of Revolution Medicines (NASDAQ: RVMD), a clinical-stage drugmaker, have gained 132% this year, easily outpacing the returns of leading pharmaceutical companies such as Eli Lilly (NYSE: LLY)
3 Beaten-Down Stocks With GLP-1 Exposure to Buy and Hold
The first GLP-1 medicine was approved in the U.S. in 2005 for the treatment of type 2 diabetes. Since then, breakthroughs have occurred in the field. Medicines in this class are now indicated for